Efficacy and tolerance profile of risperidone use in people with autism spectrum disorder in a clinic in Santarém, Pará, Brazil. A retrospective study.

Autor:	da Silva JF; Center of Biological and Health Sciences, State University of Pará, Santarém, São Paulo, Brazil., Honorato MM; Center of Biological and Health Sciences, State University of Pará, Santarém, São Paulo, Brazil., Cremaschi RMC; Department of Neurology and Neurosurgery, Federal University of São Paulo, São Paulo, Brazil., Coelho FMS; Department of Neurology and Neurosurgery, Federal University of São Paulo, São Paulo, Brazil.
Jazyk:	angličtina
Zdroj:	Journal of neurosciences in rural practice [J Neurosci Rural Pract] 2023 Apr-Jun; Vol. 14 (2), pp. 308-312. Date of Electronic Publication: 2023 Mar 20.
DOI:	10.25259/JNRP_53_2022
Abstrakt:	Objectives: This study aimed to obtain the profile of efficacy and tolerance of risperidone in the treatment of people with autism spectrum disorder. Materials and Methods: This research was a cross-sectional and retrospective study. The medical records of 100 patients diagnosed with ASD according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) were analyzed and measures of central tendency and correlation between variables such as gender, age at diagnosis, symptoms, daily dose, comorbidities, polytherapy, adverse drug effects, and outcome (improvement, worsening, and drug discontinuation) were calculated using Pearson's R test with a level of statistical significance P < 0.05. Results: The male gender was the most affected, corresponding to 80% of the participants. The mean age at diagnosis was 6.88 ± 6.24 and the mean dose was 1.89 ± 1.68 mg/day. The use of risperidone for patients with aggressiveness, hyperactivity, insomnia, or self-harm improved in 76% of patients and adverse effects were reported in 27% of cases. The presence of self-harm implied lower chances of improvement ( P = 0.05/r = -0.20). Adverse effects were strong predictors of discontinuation ( P = 0.01/r = 0.39), and epileptic patients were more likely to have them ( P = 0.02/r = 0.20). Male gender was associated with dosages lower than 2 mg/day ( P = 0.05/r = 0.23). Conclusion: Risperidone is a good option in the management of secondary symptoms of ASD, generally requiring low doses and presenting an acceptable profile of adverse effects. The age of diagnosis does not affect the drug's efficiency, but it can make the management of ASD difficult. Competing Interests: There are no conflicts of interest. (© 2023 Published by Scientific Scholar on behalf of Journal of Neurosciences in Rural Practice.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu